Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

B-902

Supelco

Buprenorphine solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C29H41NO4
Número de CAS:
52485-79-7
Peso molecular:
467.64
Número CE:
200-659-6
Número MDL:
MFCD00198063
Código UNSPSC:
41116107
NACRES:
NA.24
En este momento no podemos mostrarle ni los precios ni la disponibilidad

grado

certified reference material

Nivel de calidad

300

Formulario

liquid

Características

SNAP-N-SPIKE®, SNAP-N-SHOOT®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

concentración

100 μg/mL in methanol

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

forensics and toxicology

Formato

single component solution

temp. de almacenamiento

2-8°C

cadena SMILES

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56

InChI

1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1

Clave InChI

RMRJXGBAOAMLHD-IHFGGWKQSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

Sold under the trade names Buprenex®, Subutex® and Suboxone®, buprenorphine is an opiate drug used to treat opioid addiction and moderate acute pain. This Certified Spiking Solution® standard is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or pharmaceutical research.

Aplicación


  • Research on Addiction and Implementation Challenges: Buprenorphine solutions have been crucial in studies exploring how systemic barriers affect the implementation of addiction treatments during concurrent public health crises, offering insights valuable for policy and practice adjustments in healthcare systems (Sharp et al., 2023).

  • Evaluating Patient-Important Measures in Opioid Use Disorder Treatments: Buprenorphine is used extensively to evaluate patient-important outcomes in medication-assisted treatment programs for opioid use disorders, aiding in the assessment of long-term recovery metrics and treatment efficacy (Reed et al., 2023).

  • Web-Based Substance Use Epidemiology Research: Buprenorphine research solutions are instrumental in developing web-based ontologies for tracking and analyzing drug abuse trends, providing a foundational tool for public health surveillance and policy-making in substance abuse epidemiology (Lokala et al., 2022).

  • Clinical Studies in Veterinary Medicine: Buprenorphine solutions are employed in veterinary medicine to assess the efficacy of transdermal applications for managing postoperative pain in animals, demonstrating its versatility and effectiveness across different biological systems (Clark et al., 2022).

  • Pain Management in Geriatric Orthopedics: The use of transdermal buprenorphine for managing pain following femur fractures in elderly patients highlights its critical role in improving postoperative care and enhancing recovery outcomes in geriatric orthopedics (Davies et al., 2022).

Información legal

Buprenex is a registered trademark of Reckitt & Colman (Overseas) Ltd
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited

Producto relacionado

Referencia del producto
Descripción
Precios

B-035

Buprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-044

Buprenorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-901

Buprenorphine-D4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-908

Buprenorphine-D4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

N-045

Norbuprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-059

Norbuprenorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-912

Norbuprenorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-920

Norbuprenorphine-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-921

Norbuprenorphine-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-100

Buprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-101

Buprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-145

Norbuprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-146

Norbuprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órganos de actuación

Eyes,Central nervous system

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Johan Menten et al.
Cancer investigation, 31(6), 412-420 (2013-06-14)
Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100
Karen L Cropsey et al.
Journal of addiction medicine, 7(3), 210-215 (2013-04-24)
This project sought to demonstrate the feasibility and acceptability of providing on-site buprenorphine treatment to individuals under community corrections supervision. Seventeen women and 13 men were enrolled on-site over a 2-week period at a community corrections location. Study participants received
Jatinder Mohan Chawla et al.
Journal of opioid management, 9(1), 35-41 (2013-05-28)
Tramadol is a synthetic opiate and a centrally acting weak m-opioid receptor agonist. The potential advantages of tramadol include ease of administration, low abuse potential, and being nonscheduled. This study compared tramadol and buprenorphine for controlling withdrawal symptoms in patients
K Wahle et al.
MMW Fortschritte der Medizin, 155 Suppl 1, 25-31 (2013-05-18)
Chronic pain in the elderly is common. Especially in the elderly inadequate treatment of pain can cause significant functional impairmentand deterioration of qualityof life. Theaim of this post-marketing surveillance study was to collect data from clinical practice on the analgesic
O Bouab et al.
Revue medicale de Bruxelles, 34(3), 132-140 (2013-08-21)
Assess the effectiveness of hospital detoxification of opiate substitution treatment (OST) in patients who failed to withdraw as outpatients. Retrospective study, conducted among patients admitted for withdrawal of OST in an addiction unit between 2005 and 2011. Referent physicians were
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico